ArticleAddiction (Abingdon, England)2026
Latent classes of sleep deficiency and correlates among patients receiving methadone treatment: A longitudinal study.
Article in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latent classes of sleep deficiency and correlates among patients receiving methadone treatment: A longitudinal study.Addiction (Abingdon, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
aimsFew studies have examined multiple domains of sleep deficiency among patients receiving methadone treatment (MT). This study investigated sleep deficiency classes and their associations with demographics, clinical characteristics and one-year treatment outcomes among patients receiving MT.
designLongitudinal study using patient-completed questionnaires on demographics, sleep, pain interference with sleep and psychological symptoms in August 2023. We used latent class analysis to group patients into sleep deficiency classes and employed multinomial logistic regression to investigate their demographic and clinical correlates. Treatment continuity and urine toxicology results over the subsequent year were analyzed in August 2024.
settingA not-for-profit federally certified opioid treatment program in Connecticut, USA.
participants1237 patients receiving MT. MEASUREMENTS: Sleep questionnaires included the Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, Brief Index of Sleep Control, STOP questionnaire and the first two items from the Cambridge-Hopkins Restless Legs Syndrome Questionnaire. Urine toxicology results and treatment continuity were extracted from the medical chart.
findingsWe identified four classes. Class I (28.0%): normal sleep/no sleep deficiency. Class II (24.8%): late sleep with increased risk for obstructive sleep apnea and restless legs syndrome. Class III (20.5%): poor sleep quality with short and late sleep. Class IV (26.6%): severe sleep deficiency. Compared with Class I, participants in Classes II-IV had statistically significantly higher odds of reporting psychological symptoms [Class II adjusted odds ratio (aOR) = 1.41, 95% confidence interval (CI) = 1.10-1.81; Class III aOR = 1.58, 95% CI = 1.23-2.03; Class IV aOR = 2.21, 95% CI = 1.72-2.84] and pain interference with sleep (for three or more days per week: Class II aOR = 5.52, 95% CI = 2.93-10.38; Class III aOR = 5.04, 95% CI = 2.62-9.69; Class IV aOR = 13.16, 95% CI = 6.98-24.84). Over the subsequent year, compared with Class I, participants in Class III had statistically significantly higher rates of positive urine toxicology results for benzodiazepines, while participants in Class IV had statistically significantly higher rates of positive urine toxicology results for fentanyl and benzodiazepines. Treatment continuity did not differ across the four classes after one year following baseline.
conclusionsVarieties of sleep deficiency compared with normal sleep appear to be associated with more severe psychological symptoms and pain interference with sleep among patients receiving methadone treatment and may serve as risk factors for substance use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.